The stock price for Oncolytics Biotech, Inc (ONCY) currently stands at $0.88. The stock experienced a substantial increase in the last session, hitting $5.01 after starting at $0.88. The stock’s lowest price was $3.05 before closing at $0.99.
In terms of market performance, Oncolytics Biotech, Inc had a fairly uneven.
52-week price history of ONCY Stock
A stock’s 52-week high and low prices can reveal much about its current status and future trajectory. Oncolytics Biotech, Inc’s current trading price is -42.28% away from its 52-week high, while its distance from the 52-week low is 171.06%. The stock’s price range during this period has spanned from $0.33 to $1.53. In the Healthcare sector, the Oncolytics Biotech, Inc’s shares surpassed a trading volume of approximately 1.1 million for the day, which was noticeably lower compared to the average daily volume of 9.1.15 million over the past three months.
Market Capitalization and Financial Performance: An In-Depth Look
Oncolytics Biotech, Inc (ONCY) has experienced a quarterly rise of 60.56% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 85.31M and boasts a workforce of 28 employees.
A Closer Look at Analysts’ Ratings for Oncolytics Biotech, Inc
As of right now, 1 analyst is rating Oncolytics Biotech, Inc as a BUY, 4 of the polled analysts branded the stock as an OVERWEIGHT, 1 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
Making Sense of Trading Volume and Moving Average Data
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.6774, with a change in price of +0.2705. Similarly, Oncolytics Biotech, Inc recorded 841,029 in trading volume during the last 100 days, posting a change of +44.16%.
Examining ONCY’s Debt-to-Equity Ratio: What You Need to Know
The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for ONCY stands at 0.15. Similarly, the long-term debt-to-equity ratio is also 0.11.
ONCY Stock Stochastic Average
Today, Oncolytics Biotech, Inc’s raw stochastic average for the past 50 days stands at 54.41%, indicating a rise from the raw stochastic average of the last 20 days, which was 15.11%. Moreover, the company’s Stochastic %K and %D values over the past 20 days were 28.74% and 39.11% respectively.
ONCY Stock Price Performance Analysis
Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. This year’s metric has recorded a Price decrease of -15.09%. However, over the past six months, we’ve seen a weaker performance of 21.14%. The price of ONCY leaped by -4.00% over the last 30 days. And in the last five days, it has fallen by -18.98%.
